TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Hutchmed (China) Limited
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet

The SACHI Phase III trial demonstrated that the combination of savolitinib (ORPATHYS®) and osimertinib (TAGRISSO®) significantly improved progression-free survival (8.2 vs 4.5 months) compared to chemotherapy in patients with EGFR-mutated NSCLC with MET amplification after EGFR-TKI progression. The combination was approved in China in June 2025 and results were published in The Lancet.

Insights
COIN   positive

Committed to increasing economic freedom and being a trusted, compliant cryptocurrency exchange in Singapore


HCM   positive

Positive Phase III trial results showing significant clinical benefit (PFS improvement of 82% over chemotherapy), regulatory approval in China, and publication in prestigious journal (The Lancet). Strong efficacy data supports commercial potential and validates the combination strategy.